Darunavir and Apixaban Interaction

Understanding the Darunavir and Apixaban Interaction

FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Darunavir belongs to the HIV Protease Inhibitor class and Apixaban belongs to the Direct Oral Anticoagulant (Factor Xa Inhibitor) class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Darunavir blocks the proteins and enzymes that normally clear apixaban from your body, leading to higher levels of the blood thinner. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Darunavir has 101 total documented interactions on file in this dataset, and Apixaban has 12. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your doctor should check the specific dosing instructions for apixaban to see if your dose needs to be changed to prevent bleeding. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Darunavir or Apixaban based on a web page, speak with your prescriber or pharmacist before making any change.